The Technical Analyst
Select Language :
Harpoon Therapeutics Inc [HARP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Harpoon Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Harpoon Therapeutics Inc is listed at the  Exchange

0.09% $23.01

America/New_York / 8 mar 2024 @ 16:00


Harpoon Therapeutics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 865.08 mill
EPS: -1.530
P/E: -15.04
Earnings Date: Aug 08, 2023
SharesOutstanding: 37.60 mill
Avg Daily Volume: 1.130 mill
RATING 2024-03-07
A-
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Neutral
DE: Strong Buy
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -15.04 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-2.56x
Company: PE -15.04 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 22.63 - 23.39

( +/- 1.64%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-11 New Leaf Biopharma Opportunities Ii, L.p. Sell 395 783 Common Stock
2024-03-11 New Leaf Biopharma Opportunities Ii, L.p. Sell 10 000 8.000% Series A Redeemable Preferred Stock
2024-03-11 New Leaf Biopharma Opportunities Ii, L.p. Sell 299 430 Common Stock Warrant (Right to Buy)
2024-03-11 New Leaf Biopharma Opportunities Ii, L.p. Sell 85 750 Common Stock Warrant (Right to Buy)
2024-03-11 Silvernail Lauren P Sell 5 000 Common Stock
INSIDER POWER
75.39
Last 96 transactions
Buy: 30 137 007 | Sell: 5 308 481

Forecast: 01:40 - $26.10

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $23.01 (0.09% )
Volume 6.40 mill
Avg. Vol. 1.130 mill
% of Avg. Vol 566.75 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Harpoon Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Harpoon Therapeutics Inc

RSI

Intraday RSI14 chart for Harpoon Therapeutics Inc

Last 10 Buy & Sell Signals For HARP

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$22.35N/AActive
Profile picture for
            Harpoon Therapeutics Inc

HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Last 10 Buy Signals

Date Signal @
ARUSDMar 29 - 04:28$41.19
KCSUSDMar 29 - 04:24$11.87
FTNUSDMar 29 - 04:141.819
ORAIUSDMar 29 - 04:0814.59
IONUSDMar 29 - 04:08452.00
MXUSDMar 29 - 04:07$4.21
RETHUSDMar 29 - 04:043 905.62
ABTUSDMar 29 - 04:041.978
XU100.ISMar 29 - 04:03PTS9 101.28
DYDXUSDMar 29 - 04:003.39

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.